FDA CHANGES IN BIOEQUIVALENCE STANDARDS SHOULD BE MADE ONLY AFTER HEARING, GPIA SUGGESTS; LEGISLATIVE CHANGES SHOULD FORESTALL PREMARIN-STYLE DEBATES
Changes in established bioequivalence standards, including bioguidances, should be made only after a hearing, "and only then if the change is shown to be necessary to establish the safety and efficacy of the product," the Generic Pharmaceutical Industry Association states in its FDA reform proposal forwarded to the House and Senate Oct. 5.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth